Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/168756
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab

AutorForero-Castro, Maribel; Robledo, Cristina; Lumbreras, Eva CSIC ORCID; Benito, Rocío; Hernandez-Sánchez, Jesus M.; Hernández-Sánchez, María; García, Juan L. CSIC ORCID CVN ; Corchete, Luis A.; Tormo, Mar; Barba, Pere; Menárguez, Javier; Ribera, Jordi; Grande, Carlos; Escoda, Lourdes; Olivier, Carmen; Carrillo Cruz, Estrella; García de Coca, Alfonso; Ribera, Josep-Maria; Hernández, Jesús M. CSIC ORCID
Palabras claveArray-based comparative genomic hybridization
Next-generation sequencing, outcome
Burkitt lymphoma
Rituximab
Fecha de publicación2016
EditorJohn Wiley & Sons
CitaciónBritish Journal of Haematology 172(3): 428-438 (2016)
ResumenThe introduction of Rituximab has improved the outcome and survival rates of Burkitt lymphoma (BL). However, early relapse and refractoriness are current limitations of BL treatment and new biological factors affecting the outcome of these patients have not been explored. This study aimed to identify the presence of genomic changes that could predict the response to new therapies in BL. Forty adolescent and adult BL patients treated with the Dose-Intensive Chemotherapy Including Rituximab (Burkimab) protocol (Spanish Programme for the Study and Treatment of Haematological Malignancies; PETHEMA) were analysed using array-based comparative genomic hybridization (CGH). In addition, the presence of TP53, TCF3 (E2A), ID3 and GNA13 mutations was assessed by next-generation sequencing (NGS). Ninety-seven per cent of the patients harboured genomic imbalances. Losses on 11q, 13q, 15q or 17p were associated with a poor response to Burkimab therapy (P = 0·038), shorter progression-free survival (PFS; P = 0·007) and overall survival (OS; P = 0·009). The integrative analysis of array-CGH and NGS showed that 26·3% (5/19) and 36·8% (7/19) of patients carried alterations in the TP53 and TCF3 genes, respectively. TP53 alterations were associated with shorter PFS (P = 0·011) while TCF3 alterations were associated with shorter OS (P = 0·032). Genetic studies could be used for risk stratification of BL patients treated with the Burkimab protocol.
DescripciónPart of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015.
URIhttp://hdl.handle.net/10261/168756
DOI10.1111/bjh.13849
Identificadoresdoi: 10.1111/bjh.13849
e-issn: 1365-2141
issn: 0007-1048
Aparece en las colecciones: (IBMCC) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

9
checked on 23-mar-2024

SCOPUSTM   
Citations

20
checked on 21-mar-2024

WEB OF SCIENCETM
Citations

18
checked on 27-feb-2024

Page view(s)

290
checked on 28-mar-2024

Download(s)

86
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.